Free Trial

Curis (CRIS) Competitors

Curis logo
$1.84 0.00 (0.00%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.81 -0.03 (-1.85%)
As of 07/25/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRIS vs. FBIO, SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHR

Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.

Curis vs. Its Competitors

Fortress Biotech (NASDAQ:FBIO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Fortress Biotech had 1 more articles in the media than Curis. MarketBeat recorded 2 mentions for Fortress Biotech and 1 mentions for Curis. Curis' average media sentiment score of 1.87 beat Fortress Biotech's score of 0.94 indicating that Curis is being referred to more favorably in the news media.

Company Overall Sentiment
Fortress Biotech Positive
Curis Very Positive

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 27.9% of Fortress Biotech shares are held by insiders. Comparatively, 5.5% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of -71.24% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Fortress Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortress Biotech-71.24% -4,712.53% -27.67%
Curis -376.08%N/A -97.14%

Fortress Biotech currently has a consensus target price of $21.00, suggesting a potential upside of 965.99%. Curis has a consensus target price of $17.00, suggesting a potential upside of 823.91%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Curis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Curis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500.

Curis has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$57.67M1.01-$46M-$2.23-0.88
Curis$10.91M1.76-$43.39M-$6.23-0.30

Summary

Fortress Biotech beats Curis on 9 of the 15 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRIS vs. The Competition

MetricCurisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.25M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.3021.3228.4120.08
Price / Sales1.76285.38432.3189.32
Price / CashN/A42.7636.2258.56
Price / Book-2.598.378.675.88
Net Income-$43.39M-$55.19M$3.25B$258.89M
7 Day Performance2.22%5.86%4.25%3.71%
1 Month Performance-17.12%17.29%10.51%11.72%
1 Year Performance-69.93%4.39%35.68%18.01%

Curis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRIS
Curis
2.5717 of 5 stars
$1.84
flat
$17.00
+823.9%
-69.4%$19.25M$10.91M-0.3060Positive News
Upcoming Earnings
FBIO
Fortress Biotech
2.5057 of 5 stars
$1.89
-3.1%
$21.00
+1,011.1%
-24.2%$57.66M$57.67M-0.85170
SABS
SAB Biotherapeutics
3.6868 of 5 stars
$2.70
+5.1%
$13.25
+390.7%
-7.6%$23.87M$1.32M-0.73140News Coverage
Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
BOLT
Bolt Biotherapeutics
2.7101 of 5 stars
$5.74
+3.8%
$50.00
+771.1%
-57.1%$10.60M$7.69M-0.1790Positive News
High Trading Volume
AMGN
Amgen
4.3994 of 5 stars
$295.87
+0.4%
$308.32
+4.2%
-8.3%$158.49B$33.42B27.0028,000Positive News
Analyst Forecast
GILD
Gilead Sciences
4.886 of 5 stars
$108.28
+0.1%
$111.38
+2.9%
+51.9%$134.62B$28.75B13.9817,600Trending News
Analyst Upgrade
VRTX
Vertex Pharmaceuticals
4.3258 of 5 stars
$458.49
-0.3%
$511.71
+11.6%
-4.6%$118.08B$11.02B0.006,100Positive News
Analyst Revision
REGN
Regeneron Pharmaceuticals
4.8248 of 5 stars
$545.53
+0.6%
$814.57
+49.3%
-47.1%$58.57B$14.20B14.2215,106Trending News
Upcoming Earnings
Analyst Forecast
ALNY
Alnylam Pharmaceuticals
4.0718 of 5 stars
$320.52
0.0%
$347.75
+8.5%
+38.2%$41.79B$2.25B-153.362,230News Coverage
Positive News
Upcoming Earnings
BIIB
Biogen
4.8068 of 5 stars
$122.68
-1.8%
$186.37
+51.9%
-42.2%$18.31B$9.68B12.117,605Upcoming Earnings
Analyst Revision
UTHR
United Therapeutics
4.9902 of 5 stars
$293.12
+0.4%
$383.08
+30.7%
-9.5%$13.17B$2.88B11.651,305Trending News
Upcoming Earnings
Insider Trade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:CRIS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners